In summary, we synthesized a simple, low-cost, and less toxic contrast agent UVHP, which targets VCAM-1 and may be useful for early-stage RA diagnosis and generate high contrast in T1-weighted MRI. This evidence concerns the gene VCAM1 and rheumatoid arthritis.